Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

AI-ECHO Hemodynamic Phenotyping in Septic Shock

AI-ECHO-Based Intelligent Hemodynamic Subtyping and Dynamic Evolution in Septic Shock: A Prospective Observational Cohort Study

This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. The study will enroll 240 adult patients with septic shock admitted to the ICU. Standardized cardiac ultrasound examinations will be performed at multiple time points, and multi-dimensional clinical-echocardiographic data will be collected. An AI-based automatic echocardiographic analysis system will be developed, and unsupervised machine learning will be applied to identify distinct hemodynamic subtypes and their dynamic evolution trajectories. This study aims to provide innovative solutions for individualized and precise hemodynamic management of septic shock.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

Background

Septic shock is the most severe stage of sepsis and is associated with mortality as high as 40%-50%. Its pathophysiological core involves profound hemodynamic disturbances resulting from complex interactions among abnormal vascular tone, relative or absolute intravascular volume deficiency, myocardial depression, and microcirculatory dysfunction.

Accumulating evidence has demonstrated substantial heterogeneity in hemodynamic profiles among patients with septic shock, including hyperdynamic states, left ventricular systolic or diastolic dysfunction, right ventricular dysfunction, and various combined phenotypes. The traditional binary classification of "warm shock" versus "cold shock" is too simplistic to capture this complexity. Such heterogeneity may partly explain why uniform treatment strategies, such as early goal-directed therapy, have yielded inconsistent results and may cause iatrogenic harm in certain subgroups.

Echocardiography has become an important tool for hemodynamic assessment in the intensive care unit (ICU). It enables noninvasive, real-time evaluation of cardiac structure and function, including left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), right ventricular function, diastolic function, cardiac output, and volume status. However, its clinical utility is limited by:

  • High operator dependency and interobserver variability;
  • Time-consuming post-processing and interpretation;
  • Difficulty in performing frequent dynamic assessments in busy ICU settings; and
  • Limited integrated analysis of multiple parameters over time.

Recent advances in artificial intelligence (AI), particularly deep learning, have shown considerable promise in medical image analysis. In echocardiography, AI has demonstrated promising performance in view classification, cardiac structure segmentation, and automated measurement of functional parameters. Meanwhile, unsupervised machine learning methods provide potential approaches for identifying disease subtypes from high-dimensional clinical data.

Building on the established "Guangzhou Sepsis Cohort" and prior research experience in AI-assisted critical care medicine, this study will integrate AI and echocardiography to systematically characterize hemodynamic phenotypes and their dynamic evolution in patients with septic shock.

Study Design

This is a prospective, single-center, observational cohort study. A total of 360 adults with septic shock admitted to the ICU of The Second Affiliated Hospital of Guangzhou Medical University are anticipated to be consecutively enrolled.

Echocardiographic examinations will be performed on Day 1, Day 3, and Day 7 after enrollment. Clinical data, laboratory measurements, treatment information, and clinical outcomes will be collected according to the study protocol.

At each echocardiographic time point, standardized point-of-care echocardiography will be performed using the same model of ultrasound system and a phased-array transducer. Cine loops of the apical four-chamber, two-chamber, and three-chamber views will be acquired for at least three cardiac cycles. Additional Doppler, M-mode, right ventricular-focused, left ventricular outflow tract, and inferior vena cava recordings will be acquired as required for the prespecified echocardiographic measurements and as detailed in the imaging manual. All images will be stored in de-identified DICOM format using a unique study identification code.

AI-derived measurements will be used for research purposes only and will not guide clinical management. Clinical treatment will be determined by the treating clinical team and will not be assigned by the study.

Clinical data collected at or near the echocardiographic examinations will include vital signs, laboratory measurements, fluid balance, vasopressor dosage, and other treatment information. Blood samples will be collected on Day 1, Day 3, and Day 7 for targeted proteomic and metabolomic analyses, as specified in the study protocol.

Study Objectives

Primary Objective:

To identify and characterize distinct hemodynamic subtypes of septic shock using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters.

Secondary Objectives:

• Longitudinal changes and dynamic evolution of hemodynamic status within 7 days after enrollment;

  • Associations of hemodynamic phenotypes with clinical severity and clinical outcomes;
  • Agreement between AI-derived and blinded expert echocardiographic measurements;
  • Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes; and
  • Exploratory development and internal validation of an early-warning model for 28-day all-cause mortality.

Study Population

Adults (≥18 years) with septic shock, diagnosed according to the Sepsis-3 criteria, who meet the eligibility criteria listed in the Eligibility section will be consecutively enrolled from the ICU of The Second Affiliated Hospital of Guangzhou Medical University. Eligible participants must have an expected ICU stay of at least 72 hours, and written informed consent must be obtained from the patient or a legally authorized representative.

Outcome Measures

Primary Outcome:

Hemodynamic subtypes identified using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters collected within 7 days after enrollment.

Secondary Outcomes:

  • Agreement between AI-derived echocardiographic measurements and blinded expert reference measurements, evaluated using intraclass correlation coefficients and Bland-Altman analyses;
  • Associations between hemodynamic subtypes and 28-day mortality;
  • Associations between hemodynamic subtypes and organ failure severity, as assessed by the Sequential Organ Failure Assessment (SOFA) score;
  • Duration of vasopressor use; and
  • ICU and hospital lengths of stay.

Statistical Analysis

Sample Size Considerations: The planned enrollment of 240 participants is based on the anticipated number of eligible septic shock admissions during the recruitment period, expected consent and follow-up completion, and study feasibility. The target sample size is intended to provide an adequate dataset for exploratory hemodynamic phenotyping and longitudinal echocardiographic analyses. As the primary objective is exploratory hemodynamic phenotyping using unsupervised analysis, no formal hypothesis-based power calculation was performed. Analyses of clinical outcomes, multi-omics profiles, and early-warning models will be considered exploratory, and model complexity will be limited according to the effective sample size and number of observed events.

Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, as appropriate. Categorical variables will be summarized as frequencies and percentages.

An unsupervised Gaussian mixture model will be applied to identify hemodynamic subtypes based on prespecified echocardiographic parameters. Clinical characteristics, treatment information, and outcomes will be compared among the identified subtypes.

Agreement between AI-derived measurements and blinded expert reference measurements will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. Targeted proteomic and metabolomic analyses will evaluate associations between protein or metabolite abundances and hemodynamic phenotype membership using methods appropriate for high-dimensional data. Where applicable, the false discovery rate will be used to account for multiple comparisons. These analyses will be considered exploratory.

An exploratory early-warning model for 28-day all-cause mortality will be developed using prespecified candidate predictors. Model discrimination will be assessed using the area under the receiver operating characteristic curve, and calibration will be evaluated using calibration plots and calibration statistics. Internal validation will be performed using bootstrap resampling or cross-validation. The number of candidate predictors and model complexity will be limited according to the number of observed events to reduce the risk of overfitting.

Multivariable logistic regression or Cox proportional hazards models will be constructed, as appropriate, to explore factors associated with adverse clinical outcomes. Repeated measurements and missing data will be addressed according to the prespecified statistical analysis plan.

Statistical analyses will be performed using SPSS, R, and Python. A two-sided P value <0.05 will be considered statistically significant, with exploratory analyses interpreted accordingly.

Studietyp

Observationell

Inskrivning (Beräknad)

240

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Weiyan Chen, MD, PhD
  • Telefonnummer: +86 13751845652
  • E-post: sam11124@163.com

Studera Kontakt Backup

Studieorter

    • Guangdong
      • Guangzhou, Guangdong, Kina, 511436
        • The Second Affiliated Hospital of Guangzhou Medical University
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Weiyan Chen, MD, PhD
        • Underutredare:
          • Lili Tao, MD
        • Underutredare:
          • Sihong Xie, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

This is a prospective observational cohort study enrolling adult patients with septic shock admitted to the ICU. The study aims to construct a multi-dimensional clinical-echocardiographic database, develop an AI-based automatic echocardiographic analysis system, identify hemodynamic subtypes using unsupervised machine learning, and reveal the dynamic evolution patterns of hemodynamics in septic shock.

Beskrivning

Inclusion Criteria:

  1. Age ≥18 years.
  2. Confirmed diagnosis of septic shock according to the Sepsis-3 criteria.
  3. Expected ICU stay of at least 72 hours.
  4. Written informed consent obtained from the patient or legally authorized representative.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded:

  1. Severe chronic heart disease, such as severe valvular heart disease or chronic heart failure with left ventricular ejection fraction (LVEF) <30%.
  2. Acute coronary syndrome.
  3. Status post cardiac surgery.
  4. Pregnancy.
  5. Inability to obtain high-quality echocardiographic images at screening.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Septic Shock Patients

Adults with septic shock admitted to the intensive care unit who meet the eligibility criteria listed in the Eligibility section. Participants will undergo standardized point-of-care echocardiography on Day 1, Day 3, and Day 7 after enrollment, together with clinical data and blood sample collection as specified in the study protocol. Clinical management will be determined by the treating clinical team and will not be assigned by the study. AI-derived echocardiographic measurements will be used for research purposes only and will not guide clinical management.

Standardized point-of-care echocardiography will be performed on Day 1, Day 3, and Day 7 after enrollment. Images will be acquired according to the imaging manual and stored in de-identified DICOM format using a unique study identification code. Echocardiographic parameters will be used for hemodynamic phenotyping and assessment of changes over time.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock
Tidsram: Within 7 days after enrollment

Identification and characterization of distinct hemodynamic phenotypes in adults with septic shock using unsupervised analysis of prespecified multidimensional echocardiographic parameters. The parameters may include measures of left ventricular systolic and diastolic function, right ventricular function, cardiac output or flow, and inferior vena cava dynamics, depending on data availability and image quality. The number and characteristics of the identified phenotypes will be determined using prespecified model selection and evaluation procedures.

Within 7 days after enrollment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Longitudinal Changes and Dynamic Evolution of Hemodynamic Status
Tidsram: Day 1, Day 3, and Day 7 after enrollment.

Serial changes in echocardiographic parameters and transitions among hemodynamic phenotypes will be evaluated during follow-up.

Day 1, Day 3, and Day 7 after enrollment.
Associations Between Hemodynamic Phenotypes and Clinical Severity and Outcomes
Tidsram: Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.

Associations of hemodynamic phenotypes with SOFA score, blood lactate, 28-day all-cause mortality, vasopressor duration, and ICU and hospital length of stay will be evaluated.

Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
Agreement Between AI-Derived and Blinded Expert Echocardiographic Measurements
Tidsram: Day 1, Day 3, and Day 7 after enrollment.

Agreement for prespecified echocardiographic parameters will be evaluated using intraclass correlation coefficients and Bland-Altman analyses.

Day 1, Day 3, and Day 7 after enrollment.
Associations Between Molecular Profiles and Hemodynamic Phenotypes
Tidsram: Day 1, Day 3, and Day 7 after enrollment.

Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes will be evaluated.

Day 1, Day 3, and Day 7 after enrollment.
Exploratory Early-Warning Model for 28-Day All-Cause Mortality
Tidsram: Predictors within 7 days; mortality through 28 days after enrollment.

An exploratory model will be developed and internally validated using clinical and echocardiographic data.

Predictors within 7 days; mortality through 28 days after enrollment.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Weiyan Chen, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

30 november 2026

Primärt slutförande (Beräknad)

9 november 2028

Avslutad studie (Beräknad)

30 november 2028

Studieregistreringsdatum

Först inskickad

25 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

2 november 2026

Första postat (Faktisk)

9 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera